ABSTRACT
Introduction
The Casitas B-cell lymphoma gene (CBL) (on chromosome 11q23.3) contains several functional domains. One of these, the C-terminal domain, gives rise to the ubiquitin activity site of the Cbl protein. By ubiquitination, the Cbl protein is targeting multiple sites of receptor tyrosine kinases, e.g. PDGFR or FLT3, resulting in negative modulation of tyrosine kinase signaling. 1 Mutations in CBL (CBL mut ) were first identified due to acquired uniparental disomy (UPD) of 11q in myeloid neoplasms. [1] [2] [3] These mutations lead to dysregulation of receptor tyrosine kinases and have the potential to transform hematopoietic cells by constitutively activating the FLT3 pathway. 4 With regards to the myeloid entities which can be affected by these mutations, Dunbar et al. identified CBL mut in 7 of 12 patients with uniparental disomy (UPD) of 11q in a cohort of 301 patients with different myeloid disorders including MDS, the MDS/MPN overlap category, MPNs, and acute myeloid leukemia (AML). 2 Grand et al. found CBL mut in 8% of atypical chronic myeloid leukemia (aCML), 6% of myelofibrosis, and 1% of hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL) cases. 3 Beer et al. documented a patient in whom a CBL mut was detectable in megakaryocytes two years before transformation from MPN to AML. 5 Very heterogeneous frequencies of CBL mut were reported in chronic myelomonocytic leukemia (CMML) ranging from 5% 6 to 22%. 7 Detailed analysis in other entities has been scarce. To evaluate the role of CBL mut in diverse MPNs and myelodysplastic/myeloproliferative neoplasms (MDS/MPN), we analyzed CBL mut in a large cohort of 636 adult patients and performed correlation studies with other molecular mutations, karyotypes, and clinical outcomes.
Design and Methods
The study cohort was made up of 636 patients: 291 patients had MPNs (polycythemia vera, PV, n=32; essential thrombocythemia, ET, n=48; primary myelofibrosis, PMF, n=19; unclassifiable MPN, n=175; so-called 'advanced MPN' (corresponding to an accelerated phase of an MPN or s-AML following a previous MPN n=17). A total of 328 Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases Bone marrow and/or peripheral blood samples underwent May Grünwald Giemsa staining and cytochemistry with myeloperoxidase (MPO) and non-specific esterase (NSE).
11 Chromosome banding analysis was carried out in all 636 cases, combined with fluorescence in situ hybridization (FISH) when necessary. 12 Patients were assigned to the following cytogenetic subgroups: normal karyotype, -Y (in male patients), gain of 1q, chromosome 7 abnormalities, trisomy 8 as sole abnormality, 12p deletion, 20q deletion, complex karyotype (defined by ≥3 chromosomal abnormalities), reciprocal translocations, other trisomies, and other alterations (Online Supplementary Table S1 ). CBL mut analysis was performed by direct Sanger sequencing covering exons 8-9.
3 Mutation loads were estimated visually from electropherograms of forward and reverse reactions as generated by Sanger sequencing and confirmed by pyrosequencing 7 in half of the cases with good correlations. In addition, BCR-ABL1 was excluded by multiplex RT (reverse transcription)-PCR in all patients. 13 Mutation analysis was carried out in subsets of patients:
NRAS (n=312), 19 KRAS (n=294), 7 and ASXL1 (n=271; by direct Sanger sequencing of exon 12). 20 Overall survival was the interval from the first evaluation of the patient´s sample in the Munich Leukemia Laboratory to death. 
Results and Discussion
In the total cohort, CBL mut were detected in 63 of 636 (9.9%) patients. Localization of the mutations in the LINKER and RING domain (exons 8-9) is shown in Figure  1A . Figure 1B ). There was no significant difference in CBL mut dependence on the RUNX1, ASXL1, and EZH2 mutation status (Table 2) .
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Summarizing these results, presence of CBL mut with the JAK2 V617F was extremely rare, and CBL mut seem to show mutual exclusiveness of JAK2exon12 and MPLW515 mutations. This gives rise to the hypothesis that CBL mut do not play a role in the 'classical' MPNs, although larger numbers of patients and the whole CBL gene would have to be analyzed for definite conclusions to be drawn. Furthermore, CBL mut were significantly underrepresented in NRAS mut (P=0.010) and KRAS mut (P=0.038) patients in our study. Also in pediatric JMML, no CBL mut case was detected in 91 patients with RAS pathway activating mutations (P<0.001) 21 and a single double mutated case only was identified in CMML. 21 Therefore, CBL mut and JAK-STAT activating mutations largely seem to exclude each other, although, here again, larger numbers of patients and the whole CBL gene would have to be analyzed for definite conclusions to be drawn. This is in accordance with the function of CBL, as it is involved in negative modulation of tyrosine kinase signaling, and, therefore, does itself finally end up in the JAK-STAT pathway. CBL mut in addition to another JAK-STAT activating mutation would probably not result in a further growth advantage for the respective cell. In contrast, Aranaz et al. found the same frequencies of CBL mut in patients with JAK2V617F-positive and -negative MPNs; however, these were only a very few cases each. 22 This suggests that such a coincidence still might occur very rarely, and it is still debatable as to whether in these rare cases two different subclones coexist. As we found a CBL mut rate of 5.9% in advanced MPNs in our study, it may be speculated that the respective mutations may contribute to disease progression in the MPNs, which is also in accordance with data on blast phase of chronic myeloid leukemia. 23, 24 Correlation of CBL mut with different cytogenetic subgroups (Online Supplementary Table S1 ) revealed the highest frequency in patients with monosomy 7. CBL mut were more frequent in patients with monosomy 7 (4 of 9, 44.4%) when compared to all remaining cases (59 of 627, 9.4%; P=0.008). CBL mut showed no significant correlations with other frequent cytogenetic subgroups, i.e. normal karyotypes, trisomy 8, or loss of Y chromosome.
Of all 63 CBL mut patients, 56 (88.9%) had only one CBL mut . Of these 56, 37 had a mutation/wild-type load of 50% or less and 19 had a load of over 50%. Eight (12.7%) cases had two different CBL mut in parallel. These cases were reanalyzed by pyrosequencing for better quantification of the mutation load, which in all cases was more than 50%. Combination of mutations and load were as follows: 1) p.Ile423Asn (38%) + p.Val430Met (40%); 2) p.Cys404Tyr (31%) + p.Arg420Gln (36%); 3) p.Cys384Arg (84%) + p.Met400Arg (7%); 4) p.His398Arg (90%) + p.Ile429_Phe434del (6%); 5) p.Cys416Ser (43%) + p.Arg420Gly (38%); 6) p.Arg420Gln (15%) + p.Arg420X (72%); 7) p.Gly415Ser (38%) + p.Arg462X (42%); 8) p.Asp390Tyr (40%) + splicing of exon 9 (31%). In all 4 cases in whom the mutations were located on the same amplicon, they were shown to appear on different alleles. Based on these data, it was not possible to draw definite conclusions as to whether these mutations were in different clones or whether both alleles of one clone were mutated. The mean mutation load in all patients was 55.0±26.0%. There was no significant difference in mean mutation load between CMML patients and the other CBL mut patients (59.0±29.1% vs. 53.1±24.4%; n.s.). Most (n=57, 90.5%) alterations were missense mutations.
Three cases had small deletions (p.Tyr368_Glu369del; p.Leu370_Tyr371del; and p.Ile429_Phe434del), 2 further cases revealed a stop mutation (p.Arg420X, and p.Arg462X), and one case an exon 9 splice mutation. Some mutations were recurrent in our cohort, such as p.Arg420Gln (n=4), p.Phe418Ser (n=3), p.Arg420Leu (n=2), p.Cys404Tyr (n=2), p.Cys416Arg (n=2), p.Ile383Met (n=2), p.Ile429Asn (n=2), and p.Leu380Pro (n=2), whereas all others were detected in single cases only ( Figure 1A © F e r r a t a S t o r t i F o u n d a t i o n Figure S1 ). Corresponding to our previous analysis, including some of the patients from this study, 7 patients with CBL mut had shorter OS when compared to those with CBL wt in the CMML-1 cohort; but this difference did not reach significance. Therefore, the prognostic value of CBL mut in CMML and in the MPNs, and its contribution to disease progression, deserves further investigation. 25 In conclusion, CBL mut are overrepresented in CMML when compared to the MPNs. They rarely occur together with JAK-STAT pathway activating mutations, but are frequently seen with other genetic markers, e.g. mutations of the TET2 gene. Because of the high frequency for CMML and certain exclusion patterns with other mutations, CBL mut analysis is a useful additive tool for differential diagnosis. 
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